[1] 中华人民共和国药典2015年版. 四部[S]. 2015: 22, 130
ChP 2015. Vol Ⅳ[S]. 2015: 22, 130
[2] SIMON A, AMARO MI, HEALY AM, et al. Development of a discriminative in vitro release test for rivastigmine transdermal patches using pharmacopeial apparatuses: USP 5 and USP 6[J]. AAPS PharmSciTech, 2017, 18(7): 2561
[3] CHANG R, RAW A, LIONBERGER R, et al. Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products[J]. AAPS J, 2013, 15(1): 41
[4] 马迅, 左宁, 陈华, 等. 透皮贴剂质量控制与评价研究进展[J]. 中国新药杂志, 2019, 28(5): 551
MA X, ZUO N, CHEN H, et al. Research progress in quality control and evaluation of transdermal patches[J]. Chin J New Drugs, 2019, 28(5): 551
[5] YANG Y, MANDA P, PAVURALA N, et al. Development and validation of in vitro-in vivo correlation(IVIVC) for estradiol transdermal drug delivery systems[J]. J Control Release, 2015, 210: 58
[6] 陈亚楠, 汪晴. 检测方法对利斯的明透皮贴剂体外释放的影响及体外渗透与体内相关性的评价[J]. 中国医药工业杂志, 2020, 51(6): 735
CHEN YN, WANG Q. Effect of determination method on in vitro release profiles of rivastigmine transdermal patches and correlation between penetration in vitro and absorption in vivo[J]. Chin J Pharm, 2020, 51(6): 735
[7] FDA. Transdermal and Topical Delivery Systems- Product Development and Quality Considerations[EB/OL]. [2022-11-03]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transdermal-and-topical-delivery-systems-product-development-and-quality-considerations
[8] VERMA G. Transdermal drug delivery system, advance development and evaluation-a review[J]. Int J Pharm Sci Res, 2017, 8(2): 385
[9] RAMADON D, MCCRUDDEN MTC, COURTENAY AJ, et al. Enhancement strategies for transdermal drug delivery systems: current trends and applications[J]. Drug Deliv Transl Res, 2021, 12(4): 758
[10] BIRD D, RAVINDRA NM. Transdermal drug delivery and patches-an overview[J]. Med Devices Sensors, 2020, 3(6): 10069
[11] 刘孟斯, 姜典卓, 岳志华, 等. 国内外透皮贴剂申报上市进展及药学研究探讨[J]. 沈阳药科大学学报, 2021, 38(8): 866
LIU MS, JIANG DZ, YUE ZH, et al. Progress and pharmaceutical research of transdermal patch in China and abroad[J]. J Shenyang Pharm Univ, 2021, 38(8): 866
[12] 卢望丁, 朱慧勇, 黄英, 等. 改良型透皮给药系统的开发要点阐述[J]. 中国医药工业杂志, 2022, 53(5): 621
LU WD, ZHU HY, HUANG Y, et al. Key points in research and development of improved transdermal drug delivery system[J]. Chin J Pharm, 2022, 53(5): 621
[13] 罗婷婷, 庾莉菊, 宁保明, 等. 外用半固体制剂质量研究与体外评价技术进展[J]. 药物分析杂志, 2022, 42(5): 748
LUO TT, YU LJ, NING BM, et al. Progress in applications of quality research and in vitro evaluation technology in topical semi-solid preparations[J]. Chin J Pharm Anal, 2022, 42(5): 748
[14] EMA. Guideline on Quality of Transdermal Patches[EB/OL]. [2022-11-03]. https://www.ema.europa.eu/en/quality-transdermal-patches
[15] OECD. Test Guideline 428: Skin Absorption: In Vitro Method[EB/OL]. [2022-11-03]. https://link.springer.com/chapter/10.1007/978-1-4939-1289-6_22
[16] BAKER RW, SANDERS LM. Controlled release delivery systems[M]//BUNGAY PM, LONSDALE HK, DEPINHO MN. Synthetic Membranes: Science, Engineering and Applications. Dordrecht: Springer Netherlands, 1986: 581
[17] TANQUARY AC, LACEY RE. Controlled Release of Biologically Active Agents [M]. New York: Plenum Press, 1974: 15
[18] HIGUCHI T. Rate of release of medicaments from ointment bases containing drugs in suspension[J]. J Pharm Sci, 1961,50(10):874
[19] EP 9.0[S]. 2016: 309
[20] USP 42[S]. 2018: 724, 1724
[21] JP. 17th Ed[S]. 2016: 141
[22] 大连科翔科技开发有限公司. 一种两用型体外透皮实验装置: 中国, 201921170042 .4[P]. 2020-05-08
Dalian Kexiang Technology Development Co., Ltd.. A Dual-purpose in vitro Transdermal Experimental Device: China, 201921170042.4[P]. 2020-05-08
[23] KHIRE A, VAVIA P. Bioavailability, bioequivalence, and in vitro-in vivo correlation of oxybutynin transdermal patch in rabbits[J]. Drug Deliv Transl Res, 2014, 4(2): 105
[24] ALI MS, BHUNIA P, SAMANTA AP, et al. Transdermal therapeutic system: study of cellulose nanocrystals influenced methylcellulose-chitosan bionanocomposites[J]. Int J Biol Macromol, 2022, 218: 556
[25] SITTISANGUANPHAN N, PARADEE N, SIRIVAT A. Hyaluronic acid and graphene oxide-incorporated hyaluronic acid hydrogels for electrically stimulated release of anticancer tamoxifen citrate[J]. J Pharm Sci, 2022, 111(6): 1633
[26] SES GmbH-Analytical Systems[EB/OL]. [2023-06-30]. https://www.ses-analysesysteme.de/index_UK.htm
[27] FDA. Draft Guidance on Acyclovir[EB/OL]. [2022-11-03]. https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acyclovir_topical%20cream_RLD%2021478_RV12-16.pdf
[28] 国家药品监督管理局药审中心. 化学仿制药透皮贴剂药学研究技术指导原则[EB/OL]. [2022-11-03]. https://www.cde.org.cn/main/news/viewInfoCommon/4fdc83d15725baf7960c60b965f51fee
CDE. Guiding Principles for Pharmaceutical Research of Transdermal Patches of Chemical Generic Drugs[EB/OL]. [2022-11-03]. https://www.cde.org.cn/main/news/viewInfoCommon/4fdc83d15725baf7960c60b965f51fee
[29] BARTOS C, SZABÓ-RÉVÉSZ P, HORVÁTH T, et al. Comparison of modern in vitro permeability methods with the aim of investigation nasal dosage forms[J]. Pharmaceutics, 2021, 13(6): 846
[30] TOJO K. Mathematical Models of Transdermal and Topical Drug Delivery[M]. Fukuoka: Biocom Systems, 2003: 11
[31] NAIK P, SHAH SM, HEANEY J, et al. Influence of test parameters on release rate of hydrocortisone from cream: study using vertical diffusion cell[J]. Dissol Technol, 2016, 23(3): 14
[32] KLEIN S. Influence of different test parameters on in vitro drug release from topical diclofenac formulations in a vertical diffusion cell setup[J]. Pharmazie, 2013, 68(7): 565
[33] BAJERSKI L, ROSSI RC, DIAS CL, et al. Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: comparison between commercial tablets[J]. AAPS PharmSciTech, 2010, 11(2): 637
[34] BALZUS B, COLOMBO M, SAHLE FF, et al. Comparison of different in vitro release methods used to investigate nanocarriers intended for dermal application[J]. Int J Pharm, 2016, 513(1): 247
[35] AMER A, ALLAM A, ABDALLAH O. Evaluation of the discriminatory power of USP dissolution method for candesartan cilexetil tablets through testing of marketed products in Egypt[J]. Dissol Technol, 2018, 25(4): 40
[36] TIFFNER KI, KANFER I, AUGUSTIN T, et al. A comprehensive approach to qualify and validate the essential parameters of an in vitro release test (IVRT) method for acyclovir cream, 5[J]. Int J Pharm, 2018, 535(1-2): 217
[37] USP-NF <1724> Semisolid Drug Products-Performance Tests [EB/OL]. 2022 [2023-06-20]. https://online.uspnf.com/uspnf/document/2_GUID-94DCFABD-D687-4F3A-A43B-09CB5D5B0B5E_10101_en-US?source=Activity
[38] FDA. Guidance for Industry Residual Drug in Transdermal and Related Drug Delivery Systems[S]. 2011
[39] European Medicines Agency. Draft Guideline on Quality and Equivalence of Topical Products[EB/OL]. [2022-11-03]. https://www.ema.europa.eu/en/quality-equivalence-topical-products
[40] PMDA. Bioequivalence Testing Guidelines for Generic Drugs for Topical Dermal Preparations [EB/OL]. [2022-11-03]. https://www.pmda.go.jp/files/000160683.pdf
[41] PMDA. Bioequivalence Test Guideline Q&A for Generic Drugs for Topical Dermal Preparations [EB/OL]. [2022-11-03]. https://www.pmda.go.jp/files/000161027.pdf
[42] SIMON GA, MAIBACH HI. The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations- an overview[J]. Skin Pharmacol Appl Skin Physiol, 2000, 13(5): 229
[43] SEKKAT N, KALIA YN, GUY RH. Porcine ear skin as a model for the assessment of transdermal drug delivery to premature neonates[J]. Pharm Res, 2004, 21(8): 1390
[44] SINGH S, ZHAO K, SINGH J. In vitro permeability and binding of hydrocarbons in pig ear and human abdominal skin[J]. Drug Chem Toxicol, 2002, 25(1): 83
[45] SATO K, SUGIBAYASHI K, MORIMOTO Y. Species-differences in percutaneous-absorption of nicorandil[J]. J Pharm Sci, 1991, 80(2): 104
[46] ROY SD, HOU S, WITHAM SL, et al. Transdermal delivery of narcotic analgesics- comparative metabolism and permeability of human cadaver skin and hairless mouse skin[J]. J Pharm Sci, 1994, 83(12): 1723
[47] RAVENZWAAY B, LEIBOLD E. A comparison between in vitro rat and human and in vivo rat skin absorption studies[J]. Hum Exp Toxicol, 2004, 23(9): 421
[48] SIMON A, AMARO MI, HEALY AM, et al. Comparative evaluation of rivastigmine permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with in vivo-in vitro correlation[J]. Int J Pharm, 2016, 512(1): 234
[49] BILLICH A, SCHMOOK F, MEINGASSNER J. Comparison of human skin or epidermis models with human and animal skin in in vitro percutaneous absorption[J]. J Invest Dermatol, 2001, 117(2): 423
[50] ROY SD, FUJIKI J, FLEITMAN JS. Permeabilities of alkyl p-aminobenzoates through living skin equivalent and cadaver skin[J]. J Pharm Sci, 1993, 82(12): 1266
[51] YANG Z, TENG Y, WANG H, et al. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation[J]. Int J Pharm, 2013, 447(1-2): 231
[52] PATEL H, JOSHI A, JOSHI A, et al. Transdermal delivery of etoposide phosphate Ⅱ: in vitro in vivo correlations (IVIVC)[J]. J Pharm Sci, 2016, 105(7): 2139
[53] KONDAMUDI PK, TIRUMALASETTY PP, MALAYANDI R, et al. Lidocaine transdermal patch: pharmacokinetic modeling and in vitro-in vivo correlation (IVIVC)[J]. AAPS PharmSciTech, 2016, 17(3): 588
[54] SHIN SH, THOMAS S, RANEY SG, et al. In vitro-in vivo correlations for nicotine transdermal delivery systems evaluated by both in vitro skin permeation (IVPT) and in vivo serum pharmacokinetics under the influence of transient heat application[J]. J Control Release, 2018, 270: 76
[55] ZAMBRANA PN, HAMMELL DC, STINCHCOMB AL. Advanced harmonization techniques result in accurate establishment of in vitro-in vivo correlations for oxybenzone from four complex dermal formulations with reapplication[J]. Drug Deliv Transl Res, 2023, 13(1): 275
[56] HAN X, LIU J, HU X, et al. Design of a long-acting rivastigmine transdermal delivery system: based on computational simulation[J]. AAPS PharmSciTech, 2022, 23(1): 54
[57] GAYNOR C, DUNNE A, DAVIS J. A comparison of the prediction accuracy of two IVIVC modelling techniques[J]. J Pharm Sci, 2008, 97(8): 3422
[58] ERHARDT EM, URSINO M, BIEWENGA J, et al. Bayesian knowledge integration for an in vitro-in vivo correlation model[J]. Biom J, 2019, 61(5): 1104
